Search Result

Results for "

cholestatic liver injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminotransferases (Transaminases) (3) Antibiotic (3) Apical Sodium-Dependent Bile Acid Transporter (4) Autophagy (1) Bacterial (3) Dengue Virus (3) Deubiquitinase (1) DUBTACs (1) Flavivirus (3) FXR (2) G protein-coupled Bile Acid Receptor 1 (1) Heme Oxygenase (HO) (1) Interleukin Related (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) Phosphodiesterase (PDE) (1) Quinone Reductase (1) Reference Standards (2) TNF Receptor (1)
By Research Areas:	Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (1) Metabolic Disease (7)

By Targets:

Aminotransferases (Transaminases) (3)

Antibiotic (3)

Apical Sodium-Dependent Bile Acid Transporter (4)

Autophagy (1)

Bacterial (3)

Dengue Virus (3)

Deubiquitinase (1)

DUBTACs (1)

Flavivirus (3)

FXR (2)

G protein-coupled Bile Acid Receptor 1 (1)

Heme Oxygenase (HO) (1)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (1)

Phosphodiesterase (PDE) (1)

Quinone Reductase (1)

Reference Standards (2)

TNF Receptor (1)

By Research Areas:

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (1)

Metabolic Disease (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109120

Odevixibat 4 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-N7121

Erythromycin estolate 1 Publications Verification	Antibiotic Bacterial Aminotransferases (Transaminases) Flavivirus Dengue Virus	Infection
Erythromycin estolate is the Erythromycin (HY-B0220) derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport .

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120R

Odevixibat (Standard) A4250 (Standard)	Apical Sodium-Dependent Bile Acid Transporter Reference Standards	Metabolic Disease
Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109083A

Cilofexor tromethamine GS-9674 tromethamine	Autophagy FXR	Metabolic Disease
Cilofexor tromethamine (GS-9674 tromethamine) is a nonsteroidal farnesene oxide receptor agonist with activity in improving markers of cholestasis and liver injury. Cilofexor tromethamine was shown to be well tolerated in patients without cirrhosis and resulted in significant improvements in liver biochemical parameters and cholestatic markers. Cilofexor tromethamine offers a potential inhibitory option for the management of primary sclerosing cholangitis .

HY-156074

Erythromycin propionate	Antibiotic Bacterial Flavivirus Dengue Virus Aminotransferases (Transaminases)	Infection
Erythromycin propionate, erythromycin (HY-B0220) derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin propionate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin propionate toxicity is related to its inhibitory effect on bile acid transport .

HY-N7121R

Erythromycin estolate (Standard)	Antibiotic Reference Standards Bacterial Aminotransferases (Transaminases) Flavivirus Dengue Virus	Infection
Erythromycin estolate (Standard) is the analytical standard of Erythromycin estolate. This product is intended for research and analytical applications. Erythromycin estolate is the Erythromycin (HY-B0220) derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport .

HY-181088

PDE3/4-IN-4	Phosphodiesterase (PDE) Interleukin Related	Metabolic Disease
PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC₅₀ values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury .

HY-182350

FXR DUBTAC modulator-1	DUBTACs Deubiquitinase	Metabolic Disease
FXR DUBTAC modulator-1 is a deubiquitinase-targeting chimeric molecule (DUBTAC) that targets FXR, with a K_a value of 2.12e-5 M for FXR. FXR DUBTAC modulator-1 recruits the deubiquitinase OTUB1, binds to OTUB1 and forms a ternary complex with FXR, reduces the polyubiquitination level of FXR, prevents FXR degradation via the ubiquitin-proteasome pathway, and elevates the protein level of FXR. FXR DUBTAC modulator-1 can be used in the research of cholestatic liver injury .

HY-183692

FXR agonist 18	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Heme Oxygenase (HO) Quinone Reductase Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
FXR agonist 18 is an orally active FXR agonist, with an EC₅₀ of 10 nM against human FXR and an EC₅₀ of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7121

Erythromycin estolate 1 Publications Verification	Infection Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Source Classification	Antibiotic Bacterial Aminotransferases (Transaminases) Flavivirus Dengue Virus
Erythromycin estolate is the Erythromycin (HY-B0220) derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport .

HY-N7121R

Erythromycin estolate (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Antibacterial Disease Research Source Classification	Antibiotic Reference Standards Bacterial Aminotransferases (Transaminases) Flavivirus Dengue Virus
Erythromycin estolate (Standard) is the analytical standard of Erythromycin estolate. This product is intended for research and analytical applications. Erythromycin estolate is the Erythromycin (HY-B0220) derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport .

Cat. No.	Product Name	Chemical Structure

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

cholestatic liver injury

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products